Immunoreactive glycoprotein GP19 Ehrlichia canis
US-9605032-B2 · Mar 28, 2017 · US
Immunoreactive glycoprotein GP19 of Ehrlichia canis
US9814768B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9814768-B2 |
| Application number | US-201715443611-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 27, 2017 |
| Priority date | Aug 31, 2006 |
| Publication date | Nov 14, 2017 |
| Grant date | Nov 14, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention concerns gp19 immunoreactive compositions for E. canis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. canis gp19 are disclosed.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of inducing an immune response against E. canis in a mammalian subject comprising administering to said subject a therapeutically effective amount of a composition comprising an isolated polypeptide comprising SEQ ID NO: 13 or an amino acid sequence at least 95% identical to SEQ ID NO: 13, wherein the polypeptide is from 24 to 75 amino acids in length. 2. The method of claim 1 , wherein the subject is a dog. 3. The method of claim 1 , wherein the composition is a pharmaceutical composition. 4. The method of claim 3 , wherein the composition is administered parenterally, subcutaneously, intravenously, intradermally, or intramuscularly.
Assignees
Inventors
Classifications
Rickettsiales (O) · CPC title
from Richettsiales (o) · CPC title
Veterinary vaccine · CPC title
Infectious diseases, e.g. generalised sepsis · CPC title
- A61K39/0233Primary
Rickettsiales, e.g. Anaplasma · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9814768B2 cover?
- The present invention concerns gp19 immunoreactive compositions for E. canis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. canis gp19 are disclosed.
- Who is the assignee on this patent?
- Res Found Dev
- What technology area does this patent fall under?
- Primary CPC classification A61K39/0233. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).